APO Research
Talk to an analyst

APO RESEARCH · REPORT

Peptide-based Drug

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Peptide-based Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

2 January 2026196 pages

Choose your research edition.

Industry ResearchPeptide-based Drug Industry Research Report 2026122 pages · $2,950 USDIndustry Growth & TrendsGlobal Peptide-based Drug Industry Growth and Trends Forecast to 2032101 pages · $3,450 USDMarket StructureGlobal Peptide-based Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Peptide-based Drug Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal Peptide-based Drug Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

The global Peptide-based Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The US & Canada market for Peptide-based Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Peptide-based Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Peptide-based Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Peptide-based Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Peptide-based Drug include Takeda, Teva, Sanofi, J & J, Novartis, Merck, Eli Lilly, AbbVie and AstraZeneca, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Includes

This report provides an overview of the global Peptide-based Drug market and its size, analyzing global market trends based on historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Peptide-based Drug and revenue in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Peptide-based Drug revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering revenue and growth rates—for 2021-2032, and evaluates and forecasts the Peptide-based Drug market size, projected growth trends, production technologies, key applications, and end-use industries.

Peptide-based Drug Segment by Company

Takeda

Teva

Sanofi

J & J

Novartis

Merck

Eli Lilly

AbbVie

AstraZeneca

The Medicines

Novo Nordisk

Ipsen

Ferring

Peptide-based Drug Segment by Type

Injection

Oral

Other

Peptide-based Drug Segment by Application

Cancer

Metabolic Disorders

Central Nervous System

Other

Peptide-based Drug Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Peptide-based Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Peptide-based Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Peptide-based Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. Revenue of Peptide-based Drug in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Peptide-based Drug industry.

Chapter 3: Detailed analysis of Peptide-based Drug companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Peptide-based Drugrevenue, gross margin, and recent development, etc.

Chapter 7: North America (US & Canada) by type, by application and by country, revenue for each segment.

Chapter 8: Europe by type, by application and by country, revenue for each segment.

Chapter 9: China by type, and by application, revenue for each segment.

Chapter 10: Asia (excluding China) by type, by application and by region, revenue for each segment.

Chapter 11: South America, Middle East & Africa by type, by application and by country, revenue for each segment.

Chapter 12: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Peptide-based Drug Market Size Growth Rate by Type (US$ Million): 2021 VS 2025 VS 2032 Table 2. Key Players of Injection Table 3. Key Players of Oral Table 4. Key Players of Other Table 4. Global Peptide-based Drug Market Size Growth Rate by Application (US$ Million): 2021 VS 2025 VS 2032 Table 5. Key Players of Cancer Table 6. Key Players of Metabolic Disorders Table 7. Key Players of Central Nervous System Table 8. Key Players of Other Table 9. Global Peptide-based Drug Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 10. Global Peptide-based Drug Market Size by Region (2021-2026) & (US$ Million) Table 11. Global Peptide-based Drug Market Share by Region (2021-2026) Table 12. Global Peptide-based Drug Market Size by Region (2027-2032) & (US$ Million) Table 13. Global Peptide-based Drug Market Share by Region (2027-2032) Table 14. Peptide-based Drug Industry Trends Table 15. Peptide-based Drug Industry Drivers Table 16. Peptide-based Drug Industry Opportunities and Challenges Table 17. Peptide-based Drug Industry Restraints Table 18. Global Peptide-based Drug Revenue by Company (US$ Million) & (2021-2026) Table 19. Global Peptide-based Drug Revenue Market Share by Company (2021-2026) Table 20. Global Peptide-based Drug Players Revenue Ranking, 2024 VS 2025 VS 2026 Table 21. Global Peptide-based Drug Key Company Head Office and Area Served Table 22. Global Peptide-based Drug Company, Product Type & Application Table 23. Global Peptide-based Drug Company Establishment Date Table 24. Global Company Market Concentration Ratio (CR5 and HHI) Table 25. Global Peptide-based Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 26. Global Peptide-based Drug Market Size by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Peptide-based Drug Market Size by Type (2021-2026) & (US$ Million) Table 28. Global Peptide-based Drug Market Size by Type (2027-2032) & (US$ Million) Table 29. Global Peptide-based Drug Revenue Market Share by Type (2021-2026) Table 30. Global Peptide-based Drug Revenue Market Share by Type (2027-2032) Table 31. Global Peptide-based Drug Market Size by Application 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Peptide-based Drug Market Size by Application (2021-2026) & (US$ Million) Table 33. Global Peptide-based Drug Market Size by Application (2027-2032) & (US$ Million) Table 34. Global Peptide-based Drug Revenue Market Share by Application (2021-2026) Table 35. Global Peptide-based Drug Revenue Market Share by Application (2027-2032) Table 36. Takeda Company Information Table 37. Takeda Business Overview Table 38. Takeda Peptide-based Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 39. Takeda Peptide-based Drug Product Portfolio Table 40. Takeda Recent Development Table 41. Teva Company Information Table 42. Teva Business Overview Table 43. Teva Peptide-based Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 44. Teva Peptide-based Drug Product Portfolio Table 45. Teva Recent Development Table 46. Sanofi Company Information Table 47. Sanofi Business Overview Table 48. Sanofi Peptide-based Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 49. Sanofi Peptide-based Drug Product Portfolio Table 50. Sanofi Recent Development Table 51. J & J Company Information Table 52. J & J Business Overview Table 53. J & J Peptide-based Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 54. J & J Peptide-based Drug Product Portfolio Table 55. J & J Recent Development Table 56. Novartis Company Information Table 57. Novartis Business Overview Table 58. Novartis Peptide-based Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 59. Novartis Peptide-based Drug Product Portfolio Table 60. Novartis Recent Development Table 61. Merck Company Information Table 62. Merck Business Overview Table 63. Merck Peptide-based Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 64. Merck Peptide-based Drug Product Portfolio Table 65. Merck Recent Development Table 66. Eli Lilly Company Information Table 67. Eli Lilly Business Overview Table 68. Eli Lilly Peptide-based Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 69. Eli Lilly Peptide-based Drug Product Portfolio Table 70. Eli Lilly Recent Development Table 71. AbbVie Company Information Table 72. AbbVie Business Overview Table 73. AbbVie Peptide-based Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 74. AbbVie Peptide-based Drug Product Portfolio Table 75. AbbVie Recent Development Table 76. AstraZeneca Company Information Table 77. AstraZeneca Business Overview Table 78. AstraZeneca Peptide-based Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 79. AstraZeneca Peptide-based Drug Product Portfolio Table 80. AstraZeneca Recent Development Table 81. The Medicines Company Information Table 82. The Medicines Business Overview Table 83. The Medicines Peptide-based Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 84. The Medicines Peptide-based Drug Product Portfolio Table 85. The Medicines Recent Development Table 86. Novo Nordisk Company Information Table 87. Novo Nordisk Business Overview Table 88. Novo Nordisk Peptide-based Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 89. Novo Nordisk Peptide-based Drug Product Portfolio Table 90. Novo Nordisk Recent Development Table 91. Ipsen Company Information Table 92. Ipsen Business Overview Table 93. Ipsen Peptide-based Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 94. Ipsen Peptide-based Drug Product Portfolio Table 95. Ipsen Recent Development Table 96. Ferring Company Information Table 97. Ferring Business Overview Table 98. Ferring Peptide-based Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 99. Ferring Peptide-based Drug Product Portfolio Table 100. Ferring Recent Development Table 101. North America Peptide-based Drug Market Size by Type (2021-2026) & (US$ Million) Table 102. North America Peptide-based Drug Market Size by Type (2027-2032) & (US$ Million) Table 103. North America Peptide-based Drug Market Size by Application (2021-2026) & (US$ Million) Table 104. North America Peptide-based Drug Market Size by Application (2027-2032) & (US$ Million) Table 105. North America Peptide-based Drug Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 106. North America Peptide-based Drug Market Size by Country (2021-2026) Table 107. North America Peptide-based Drug Market Size by Country (2027-2032) Table 108. Europe Peptide-based Drug Market Size by Type (2021-2026) & (US$ Million) Table 109. Europe Peptide-based Drug Market Size by Type (2027-2032) & (US$ Million) Table 110. Europe Peptide-based Drug Market Size by Application (2021-2026) & (US$ Million) Table 111. Europe Peptide-based Drug Market Size by Application (2027-2032) & (US$ Million) Table 112. Europe Peptide-based Drug Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 113. Europe Peptide-based Drug Market Size by Country (2021-2026) Table 114. Europe Peptide-based Drug Market Size by Country (2027-2032) Table 115. China Peptide-based Drug Market Size by Type (2021-2026) & (US$ Million) Table 116. China Peptide-based Drug Market Size by Type (2027-2032) & (US$ Million) Table 117. China Peptide-based Drug Market Size by Application (2021-2026) & (US$ Million) Table 118. China Peptide-based Drug Market Size by Application (2027-2032) & (US$ Million) Table 119. Asia Peptide-based Drug Market Size by Type (2021-2026) & (US$ Million) Table 120. Asia Peptide-based Drug Market Size by Type (2027-2032) & (US$ Million) Table 121. Asia Peptide-based Drug Market Size by Application (2021-2026) & (US$ Million) Table 122. Asia Peptide-based Drug Market Size by Application (2027-2032) & (US$ Million) Table 123. Asia Peptide-based Drug Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 124. Asia Peptide-based Drug Market Size by Country (2021-2026) Table 125. Asia Peptide-based Drug Market Size by Country (2027-2032) Table 126. South America, Middle East & Africa Peptide-based Drug Market Size by Type (2021-2026) & (US$ Million) Table 127. South America, Middle East & Africa Peptide-based Drug Market Size by Type (2027-2032) & (US$ Million) Table 128. South America, Middle East & Africa Peptide-based Drug Market Size by Application (2021-2026) & (US$ Million) Table 129. South America, Middle East & Africa Peptide-based Drug Market Size by Application (2027-2032) & (US$ Million) Table 130. South America, Middle East & Africa Peptide-based Drug Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 131. South America, Middle East & Africa Peptide-based Drug Market Size by Country (2021-2026) Table 132. South America, Middle East & Africa Peptide-based Drug Market Size by Country (2027-2032) Table 133. Research Programs/Design for This Report Table 134. Authors List of This Report Table 135. Secondary Sources Table 136. Primary Sources List of Figures Figure 1. Peptide-based Drug Product Image Figure 2. Global Peptide-based Drug Market Size Growth Rate by Type, 2021 VS 2025 VS 2032 (US$ Million) Figure 3. Global Peptide-based Drug Market Share by Type: 2025 VS 2032 Figure 4. Injection Image Figure 5. Oral Image Figure 6. Other Image Figure 7. Global Peptide-based Drug Market Size Growth Rate by Application, 2021 VS 2025 VS 2032 (US$ Million) Figure 8. Global Peptide-based Drug Market Share by Application: 2025 VS 2032 Figure 9. Cancer Image Figure 10. Metabolic Disorders Image Figure 11. Central Nervous System Image Figure 12. Other Image Figure 13. Global Peptide-based Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 14. Global Peptide-based Drug Market Size (2021-2032) & (US$ Million) Figure 15. Global Peptide-based Drug Market Share by Region: 2025 VS 2032 Figure 16. Years Considered Figure 17. Global Peptide-based Drug Market Share by Players in 2025 Figure 18. Global Top 5 and 10 Peptide-based Drug Players Market Share by Revenue in 2025 Figure 19. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 20. Global Peptide-based Drug Market Size by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 21. Global Peptide-based Drug Revenue Market Share by Type (2021-2032) Figure 22. Global Peptide-based Drug Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global Peptide-based Drug Revenue Market Share by Application (2021-2032) Figure 24. North America Peptide-based Drug Market Size (2021-2032) & (US$ Million) Figure 25. North America Peptide-based Drug Market Share by Type (2021-2032) Figure 26. North America Peptide-based Drug Market Share by Application (2021-2032) Figure 27. North America Peptide-based Drug Market Share by Country (2021-2032) Figure 28. United States Peptide-based Drug Market Size (2021-2032) & (US$ Million) Figure 29. Canada Peptide-based Drug Market Size (2021-2032) & (US$ Million) Figure 30. Mexico Peptide-based Drug Market Size (2021-2032) & (US$ Million) Figure 31. Europe Peptide-based Drug Market Size (2021-2032) & (US$ Million) Figure 32. Europe Peptide-based Drug Market Share by Type (2021-2032) Figure 33. Europe Peptide-based Drug Market Share by Application (2021-2032) Figure 34. Europe Peptide-based Drug Market Share by Country (2021-2032) Figure 35. Germany Peptide-based Drug Market Size (2021-2032) & (US$ Million) Figure 36. France Peptide-based Drug Market Size (2021-2032) & (US$ Million) Figure 37. U.K. Peptide-based Drug Market Size (2021-2032) & (US$ Million) Figure 38. Italy Peptide-based Drug Market Size (2021-2032) & (US$ Million) Figure 39. Russia Peptide-based Drug Market Size (2021-2032) & (US$ Million) Figure 40. Nordic Countries Peptide-based Drug Market Size (2021-2032) & (US$ Million) Figure 41. China Peptide-based Drug Market Size (2021-2032) & (US$ Million) Figure 42. China Peptide-based Drug Market Share by Type (2021-2032) Figure 43. China Peptide-based Drug Market Share by Application (2021-2032) Figure 44. Asia Peptide-based Drug Market Size (2021-2032) & (US$ Million) Figure 45. Asia Peptide-based Drug Market Share by Type (2021-2032) Figure 46. Asia Peptide-based Drug Market Share by Application (2021-2032) Figure 47. Asia Peptide-based Drug Market Share by Country (2021-2032) Figure 48. Japan Peptide-based Drug Market Size (2021-2032) & (US$ Million) Figure 49. South Korea Peptide-based Drug Market Size (2021-2032) & (US$ Million) Figure 50. Taiwan Peptide-based Drug Market Size (2021-2032) & (US$ Million) Figure 51. Southeast Asia Peptide-based Drug Market Size (2021-2032) & (US$ Million) Figure 52. India Peptide-based Drug Market Size (2021-2032) & (US$ Million) Figure 53. Australia Peptide-based Drug Market Size (2021-2032) & (US$ Million) Figure 54. South America, Middle East & Africa Peptide-based Drug Market Size (2021-2032) & (US$ Million) Figure 55. South America, Middle East & Africa Peptide-based Drug Market Share by Type (2021-2032) Figure 56. South America, Middle East & Africa Peptide-based Drug Market Share by Application (2021-2032) Figure 57. South America, Middle East & Africa Peptide-based Drug Market Share by Country (2021-2032) Figure 58. Brazil Peptide-based Drug Market Size (2021-2032) & (US$ Million) Figure 59. South Africa Peptide-based Drug Market Size (2021-2032) & (US$ Million) Figure 60. Saudi Arabia Peptide-based Drug Market Size (2021-2032) & (US$ Million) Figure 61. Turkey Peptide-based Drug Market Size (2021-2032) & (US$ Million) Figure 62. Argentina Peptide-based Drug Market Size (2021-2032) & (US$ Million) Figure 63. UAE Peptide-based Drug Market Size (2021-2032) & (US$ Million) Figure 64. Egypt Peptide-based Drug Market Size (2021-2032) & (US$ Million) Figure 65. Chile Peptide-based Drug Market Size (2021-2032) & (US$ Million) Figure 66. Research Process Figure 67. Key Executives Interviewed

Scope & coverage.

Types
  • Injection
  • Oral
  • Other
Applications
  • Cancer
  • Metabolic Disorders
  • Central Nervous System
  • Other
Companies covered
  • Takeda
  • Teva
  • Sanofi
  • J & J
  • Novartis
  • Merck
  • Eli Lilly
  • AbbVie
  • AstraZeneca
  • The Medicines
  • Novo Nordisk
  • Ipsen
  • Ferring

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Market Analysis by Type
  3. 1.2.1 Global Peptide-based Drug Market Size Growth Rate by Type: 2021 VS 2025 VS 2032
  4. 1.2.2 Injection
  5. 1.2.3 Oral
  6. 1.2.4 Other
  7. 1.3 Market Analysis by Application
  8. 1.3.1 Global Peptide-based Drug Market Size Growth Rate by Application: 2021 VS 2025 VS 2032
  9. 1.3.2 Cancer
  10. 1.3.3 Metabolic Disorders
  11. 1.3.4 Central Nervous System
  12. 1.3.5 Other
  13. 1.4 Global Market Growth Prospects
  14. 1.5 Global Peptide-based Drug Growth Trends by Region
  15. 1.5.1 Global Peptide-based Drug Market Size by Region: 2021 VS 2025 VS 2032
  16. 1.5.2 Peptide-based Drug Market Size by Region (2021-2026)
  17. 1.5.3 Peptide-based Drug Market Size by Region (2027-2032)
  18. 1.6 Assumptions and Limitations
  19. 1.7 Study Goals and Objectives
  20. 1.8 Years Considered
2 Global Peptide-based Drug Market Dynamics
  1. 2.1 Peptide-based Drug Industry Trends
  2. 2.2 Peptide-based Drug Industry Drivers
  3. 2.3 Peptide-based Drug Industry Opportunities and Challenges
  4. 2.4 Peptide-based Drug Industry Restraints
3 Competitive Landscape by Company
  1. 3.1 Global Peptide-based Drug Revenue by Company (2021-2026)
  2. 3.2 Global Peptide-based Drug Players Revenue Ranking, 2024 VS 2025 VS 2026
  3. 3.3 Global Peptide-based Drug Key Company Head office and Area Served
  4. 3.4 Global Peptide-based Drug Company, Product Type & Application
  5. 3.5 Global Peptide-based Drug Company Establishment Date
  6. 3.6 Market Competitive Analysis
  7. 3.6.1 Global Peptide-based Drug Market CR5 and HHI
  8. 3.6.2 Global Top 5 and 10 Peptide-based Drug Players Market Share by Revenue in 2025
  9. 3.6.3 2025 Peptide-based Drug Tier 1, Tier 2, and Tier 3
4 Peptide-based Drug Market by Type
  1. 4.1 Global Peptide-based Drug Market Size by Type (2021 VS 2025 VS 2032)
  2. 4.2 Global Peptide-based Drug Market Size by Type (2021-2032)
  3. 4.3 Global Peptide-based Drug Market Size Share by Type (2021-2032)
5 Peptide-based Drug Market by Application
  1. 5.1 Global Peptide-based Drug Market Size by Application (2021 VS 2025 VS 2032)
  2. 5.2 Global Peptide-based Drug Market Size by Application (2021-2032)
  3. 5.3 Global Peptide-based Drug Market Size Share by Application (2021-2032)
6 Company Profiles
  1. 6.1 Takeda
  2. 6.1.1 Takeda Company Information
  3. 6.1.2 Takeda Business Overview
  4. 6.1.3 Takeda Peptide-based Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
  5. 6.1.4 Takeda Peptide-based Drug Product Portfolio
  6. 6.1.5 Takeda Recent Developments
  7. 6.2 Teva
  8. 6.2.1 Teva Company Information
  9. 6.2.2 Teva Business Overview
  10. 6.2.3 Teva Peptide-based Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
  11. 6.2.4 Teva Peptide-based Drug Product Portfolio
  12. 6.2.5 Teva Recent Developments
  13. 6.3 Sanofi
  14. 6.3.1 Sanofi Company Information
  15. 6.3.2 Sanofi Business Overview
  16. 6.3.3 Sanofi Peptide-based Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
  17. 6.3.4 Sanofi Peptide-based Drug Product Portfolio
  18. 6.3.5 Sanofi Recent Developments
  19. 6.4 J & J
  20. 6.4.1 J & J Company Information
  21. 6.4.2 J & J Business Overview
  22. 6.4.3 J & J Peptide-based Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
  23. 6.4.4 J & J Peptide-based Drug Product Portfolio
  24. 6.4.5 J & J Recent Developments
  25. 6.5 Novartis
  26. 6.5.1 Novartis Company Information
  27. 6.5.2 Novartis Business Overview
  28. 6.5.3 Novartis Peptide-based Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
  29. 6.5.4 Novartis Peptide-based Drug Product Portfolio
  30. 6.5.5 Novartis Recent Developments
  31. 6.6 Merck
  32. 6.6.1 Merck Company Information
  33. 6.6.2 Merck Business Overview
  34. 6.6.3 Merck Peptide-based Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
  35. 6.6.4 Merck Peptide-based Drug Product Portfolio
  36. 6.6.5 Merck Recent Developments
  37. 6.7 Eli Lilly
  38. 6.7.1 Eli Lilly Company Information
  39. 6.7.2 Eli Lilly Business Overview
  40. 6.7.3 Eli Lilly Peptide-based Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
  41. 6.7.4 Eli Lilly Peptide-based Drug Product Portfolio
  42. 6.7.5 Eli Lilly Recent Developments
  43. 6.8 AbbVie
  44. 6.8.1 AbbVie Company Information
  45. 6.8.2 AbbVie Business Overview
  46. 6.8.3 AbbVie Peptide-based Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
  47. 6.8.4 AbbVie Peptide-based Drug Product Portfolio
  48. 6.8.5 AbbVie Recent Developments
  49. 6.9 AstraZeneca
  50. 6.9.1 AstraZeneca Company Information
  51. 6.9.2 AstraZeneca Business Overview
  52. 6.9.3 AstraZeneca Peptide-based Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
  53. 6.9.4 AstraZeneca Peptide-based Drug Product Portfolio
  54. 6.9.5 AstraZeneca Recent Developments
  55. 6.10 The Medicines
  56. 6.10.1 The Medicines Company Information
  57. 6.10.2 The Medicines Business Overview
  58. 6.10.3 The Medicines Peptide-based Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
  59. 6.10.4 The Medicines Peptide-based Drug Product Portfolio
  60. 6.10.5 The Medicines Recent Developments
  61. 6.11 Novo Nordisk
  62. 6.11.1 Novo Nordisk Company Information
  63. 6.11.2 Novo Nordisk Business Overview
  64. 6.11.3 Novo Nordisk Peptide-based Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
  65. 6.11.4 Novo Nordisk Peptide-based Drug Product Portfolio
  66. 6.11.5 Novo Nordisk Recent Developments
  67. 6.12 Ipsen
  68. 6.12.1 Ipsen Company Information
  69. 6.12.2 Ipsen Business Overview
  70. 6.12.3 Ipsen Peptide-based Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
  71. 6.12.4 Ipsen Peptide-based Drug Product Portfolio
  72. 6.12.5 Ipsen Recent Developments
  73. 6.13 Ferring
  74. 6.13.1 Ferring Company Information
  75. 6.13.2 Ferring Business Overview
  76. 6.13.3 Ferring Peptide-based Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
  77. 6.13.4 Ferring Peptide-based Drug Product Portfolio
  78. 6.13.5 Ferring Recent Developments
7 North America
  1. 7.1 North America Peptide-based Drug Market Size (2021-2032)
  2. 7.2 North America Peptide-based Drug Market Size by Type
  3. 7.2.1 North America Peptide-based Drug Market Size by Type (2021-2026)
  4. 7.2.2 North America Peptide-based Drug Market Size by Type (2027-2032)
  5. 7.2.3 North America Peptide-based Drug Market Share by Type (2021-2032)
  6. 7.3 North America Peptide-based Drug Market Size by Application
  7. 7.3.1 North America Peptide-based Drug Market Size by Application (2021-2026)
  8. 7.3.2 North America Peptide-based Drug Market Size by Application (2027-2032)
  9. 7.3.3 North America Peptide-based Drug Market Share by Application (2021-2032)
  10. 7.4 North America Peptide-based Drug Market Size by Country
  11. 7.4.1 North America Peptide-based Drug Market Size by Country (2021 VS 2025 VS 2032)
  12. 7.4.2 North America Peptide-based Drug Market Size by Country (2021-2026)
  13. 7.4.3 North America Peptide-based Drug Market Size by Country (2027-2032)
  14. 7.4.4 North America Peptide-based Drug Market Share by Country (2021-2032)
  15. 7.4.5 United States
  16. 7.4.6 Canada
  17. 7.4.7 Mexico
8 Europe
  1. 8.1 Europe Peptide-based Drug Market Size (2021-2032)
  2. 8.2 Europe Peptide-based Drug Market Size by Type
  3. 8.2.1 Europe Peptide-based Drug Market Size by Type (2021-2026)
  4. 8.2.2 Europe Peptide-based Drug Market Size by Type (2027-2032)
  5. 8.2.3 Europe Peptide-based Drug Market Share by Type (2021-2032)
  6. 8.3 Europe Peptide-based Drug Market Size by Application
  7. 8.3.1 Europe Peptide-based Drug Market Size by Application (2021-2026)
  8. 8.3.2 Europe Peptide-based Drug Market Size by Application (2027-2032)
  9. 8.3.3 Europe Peptide-based Drug Market Share by Application (2021-2032)
  10. 8.4 Europe Peptide-based Drug Market Size by Country
  11. 8.4.1 Europe Peptide-based Drug Market Size by Country (2021 VS 2025 VS 2032)
  12. 8.4.2 Europe Peptide-based Drug Market Size by Country (2021-2026)
  13. 8.4.3 Europe Peptide-based Drug Market Size by Country (2027-2032)
  14. 8.4.4 Europe Peptide-based Drug Market Share by Country (2021-2032)
  15. 8.4.5 Germany
  16. 8.4.6 France
  17. 8.4.7 U.K.
  18. 8.4.8 Italy
  19. 8.4.9 Russia
  20. 8.4.10 Nordic Countries
9 China
  1. 9.1 China Peptide-based Drug Market Size (2021-2032)
  2. 9.2 China Peptide-based Drug Market Size by Type
  3. 9.2.1 China Peptide-based Drug Market Size by Type (2021-2026)
  4. 9.2.2 China Peptide-based Drug Market Size by Type (2027-2032)
  5. 9.2.3 China Peptide-based Drug Market Share by Type (2021-2032)
  6. 9.3 China Peptide-based Drug Market Size by Application
  7. 9.3.1 China Peptide-based Drug Market Size by Application (2021-2026)
  8. 9.3.2 China Peptide-based Drug Market Size by Application (2027-2032)
  9. 9.3.3 China Peptide-based Drug Market Share by Application (2021-2032)
10 Asia (Excluding China)
  1. 10.1 Asia Peptide-based Drug Market Size (2021-2032)
  2. 10.2 Asia Peptide-based Drug Market Size by Type
  3. 10.2.1 Asia Peptide-based Drug Market Size by Type (2021-2026)
  4. 10.2.2 Asia Peptide-based Drug Market Size by Type (2027-2032)
  5. 10.2.3 Asia Peptide-based Drug Market Share by Type (2021-2032)
  6. 10.3 Asia Peptide-based Drug Market Size by Application
  7. 10.3.1 Asia Peptide-based Drug Market Size by Application (2021-2026)
  8. 10.3.2 Asia Peptide-based Drug Market Size by Application (2027-2032)
  9. 10.3.3 Asia Peptide-based Drug Market Share by Application (2021-2032)
  10. 10.4 Asia Peptide-based Drug Market Size by Country
  11. 10.4.1 Asia Peptide-based Drug Market Size by Country (2021 VS 2025 VS 2032)
  12. 10.4.2 Asia Peptide-based Drug Market Size by Country (2021-2026)
  13. 10.4.3 Asia Peptide-based Drug Market Size by Country (2027-2032)
  14. 10.4.4 Asia Peptide-based Drug Market Share by Country (2021-2032)
  15. 10.4.5 Japan
  16. 10.4.6 South Korea
  17. 10.4.7 Taiwan
  18. 10.4.8 Southeast Asia
  19. 10.4.9 India
  20. 10.4.10 Australia
11 South America, Middle East & Africa
  1. 11.1 South America, Middle East & Africa Peptide-based Drug Market Size (2021-2032)
  2. 11.2 South America, Middle East & Africa Peptide-based Drug Market Size by Type
  3. 11.2.1 South America, Middle East & Africa Peptide-based Drug Market Size by Type (2021-2026)
  4. 11.2.2 South America, Middle East & Africa Peptide-based Drug Market Size by Type (2027-2032)
  5. 11.2.3 South America, Middle East & Africa Peptide-based Drug Market Share by Type (2021-2032)
  6. 11.3 South America, Middle East & Africa Peptide-based Drug Market Size by Application
  7. 11.3.1 South America, Middle East & Africa Peptide-based Drug Market Size by Application (2021-2026)
  8. 11.3.2 South America, Middle East & Africa Peptide-based Drug Market Size by Application (2027-2032)
  9. 11.3.3 South America, Middle East & Africa Peptide-based Drug Market Share by Application (2021-2032)
  10. 11.4 South America, Middle East & Africa Peptide-based Drug Market Size by Country
  11. 11.4.1 South America, Middle East & Africa Peptide-based Drug Market Size by Country (2021 VS 2025 VS 2032)
  12. 11.4.2 South America, Middle East & Africa Peptide-based Drug Market Size by Country (2021-2026)
  13. 11.4.3 South America, Middle East & Africa Peptide-based Drug Market Size by Country (2027-2032)
  14. 11.4.4 South America, Middle East & Africa Peptide-based Drug Market Share by Country (2021-2032)
  15. 11.4.5 Brazil
  16. 11.4.6 South Africa
  17. 11.4.7 Saudi Arabia
  18. 11.4.8 Turkey
  19. 11.4.9 Argentina
  20. 11.4.9 UAE
  21. 11.4.9 Egypt
  22. 11.4.9 Chile
12 Concluding Insights
    13 Appendix
    1. 13.1 Reasons for Doing This Study
    2. 13.2 Research Methodology
    3. 13.3 Research Process
    4. 13.4 Authors List of This Report
    5. 13.5 Data Source
    6. 13.5.1 Secondary Sources
    7. 13.5.2 Primary Sources
    8. 13.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst